Results 81 to 90 of about 616,871 (170)

Data from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia

<div>Abstract<p>T-lineage acute lymphoblastic leukemia (T-ALL) lacks effective targeted therapies, with poor outcomes in relapsed/refractory (R/R) disease.
Olatoyosi Odenike, Jason X. Cheng, Francis Burrows, Michael W. Drazer, Diren Arda Karaoglu, Anand A. Patel, Giorgia Giordano, Arjun Dhar, Linda Kessler, Wendy Stock, Olivia Arnold, Michael J. Thirman, Zachary Chan, Kathryn Shimamoto, Caner Saygin, Hamed R. Youshanlouei, Adam S. DuVall   +16 more
core   +1 more source

Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors. [PDF]

Blood Cancer J
Shukla N, Charalambous K, Li S, Ko KH, Casanova H, Buehler E, Cobbs C, Patel R, Brannon AR, Ewalt MD, Sulis ML, Carroll WL, Arcila ME, Mohibullah N, Berger M, Levine RL, Stein EM, Shah R, Cai SF.   +18 more
europepmc   +1 more source

A menin-KMT2A inhibitor to overcome resistance

Blood
Heckman Caroline A., Heckman Caroline A.
openaire   +2 more sources

Development of an orally bioavailable selective inhibitor of the menin-MLL

Genes & Diseases, 2023
Hai-Jing Zhong, Wanhe Wang, Wei Zhou, Jia-Xin Liang, Yung-Chi Cheng, Dik-Lung Ma, Chung-Hang Leung   +6 more
openaire   +3 more sources

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report. [PDF]

Blood Adv
Zeidner JF, Jain J, Welkie RL, Huang Y, Swords RT, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Handa S, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Mims AS, Byrd JC, Borate U.   +34 more
europepmc   +1 more source

Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. [PDF]

Cancer Discov
Gordon SJV, Perner F, MacPherson L, Fennell KA, Wenge DV, Bourgeois W, Klaus T, Plenge T, Murat A, Petrovic J, Horvath J, Cao JQ, Lapek JD, Uryu S, White JR, Lam EYN, Mu XJ, Chan YC, Gillespie A, Blyth BJ, Camerino MA, Bozikis YE, Holze H, Knezevic K, Balic J, Stupple PA, Street IP, Monahan BJ, Sharma S, Wainwright EN, Vassiliadis D, Paul TA, Armstrong SA, Dawson MA.   +33 more
europepmc   +1 more source

MLL-menin and FLT3 inhibitors team up for AML [PDF]

Blood, 2020
openaire   +2 more sources

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. [PDF]

Leukemia
Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Zwaan CM, Pollard JA, DiNardo CD, Kadia TM, Guest E, Short NJ, McCall D, Daver N, Nunez C, Haddad FG, Garcia M, Bhalla KN, Maiti A, Catueno S, Fiskus W, Carter BZ, Gibson A, Roth M, Khazal S, Tewari P, Abbas HA, Bourgeois W, Andreeff M, Shukla NN, Truong DD, Connors J, Ludwig JA, Stutterheim J, Salzer E, Juul-Dam KL, Sasaki K, Mahadeo KM, Tasian SK, Borthakur G, Dickson S, Jain N, Jabbour E, Meshinchi S, Garcia-Manero G, Ravandi F, Stein EM, Kolb EA, Issa GC.   +46 more
europepmc   +1 more source

Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. [PDF]

Mol Cancer Ther
Shimamoto K, Karaoglu DA, Arnold O, Dhar A, Chan Z, Giordano G, Cheng JX, Youshanlouei HR, Patel AA, DuVall AS, Drazer MW, Kessler L, Burrows F, Odenike O, Thirman MJ, Stock W, Saygin C.   +16 more
europepmc   +1 more source

Targeting DOT1L Epigenetic Moonlighting in MLL-Rearranged Leukemia. [PDF]

Cells
Gupta DG, Gupta M, Othman AH, Memon UA, Schiltz GE, Abdulkadir SA.   +5 more
europepmc   +1 more source